Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 20, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Schmidt Maintained (BGNE) at Strong Buy with Increased Target to $350 on, Jan 20th, 2023
Michael Schmidt of Guggenheim, Maintained "BeiGene, Ltd." (BGNE) at Strong Buy with Increased Target from $290 to $350 on, Jan 20th, 2023.
Michael has made no other calls on BGNE in the last 4 months.
There is 1 other peer that has a rating on BGNE. Out of the 1 peers that are also analyzing BGNE, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $295 on, Thursday, October 13th, 2022
